Neurogene Inc. (NGNE) Financial Statements (2026 and earlier)

Company Profile

Business Address 535 W 24TH STREET
NEW YORK, NY 10011
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:312,400197,15796,384142,467192,556143,093
Cash and cash equivalent136,586148,21037,887142,467192,556143,093
Short-term investments175,81948,94758,497   
Other undisclosed cash, cash equivalents, and short-term investments(5)     
Prepaid expense1,8891,496    
Deferred costs      
Other current assets9811,0952,7501,5221,966 
Other undisclosed current assets653600   503
Total current assets:315,923200,34899,134143,989194,522143,596
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization7198500200  
Operating lease, right-of-use asset3,0003,6819,71510,76610,154770
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization15,42217,174  3,5702,060
Intangible asset, including goodwill, after accumulated amortization    128347567
Intangible asset, excluding goodwill, after accumulated amortization    128347567
Restricted cash and investments339508    
Other noncurrent assets9757649361,9281,926 
Other undisclosed noncurrent assets   5,6636,252 30
Total noncurrent assets:19,80722,22516,81419,27415,9973,427
TOTAL ASSETS:335,730222,573115,948163,263210,519147,023
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,06720,0915,1875,0165,4943,181
Employee-related liabilities3,2633,2441,238
Accounts payable1,3362,5964785261,3231,604
Accrued liabilities9,73117,4954,7091,227927339
Debt54421405549618
Other undisclosed current liabilities4,0362,8405,7353,5652,346944
Total current liabilities:15,15722,97311,0628,6367,8894,743
Noncurrent Liabilities
Long-term debt and lease obligation266523311,76311,414593
Finance lease, liability266523367108146
Liabilities, other than long-term debt9,45412,50510,322   
Other liabilities51203    
Operating lease, liability9,40312,30210,32211,69611,306447
Other undisclosed noncurrent liabilities7181,006 (11,696)(11,306) 
Total noncurrent liabilities:10,19813,57610,55511,76311,414593
Total liabilities:25,35536,54921,61720,39919,3035,336
Equity
Equity, attributable to parent310,375186,02494,331142,864191,216141,687
Additional paid in capital572,673373,178545,407536,362524,022441,216
Accumulated other comprehensive loss   (21)   
Accumulated deficit(262,298)(187,154)(451,055)(393,498)(332,806)(299,529)
Total equity:310,375186,02494,331142,864191,216141,687
TOTAL LIABILITIES AND EQUITY:335,730222,573115,948163,263210,519147,023

Income Statement (P&L) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues 925     
Gross profit: 925     
Operating expenses(83,530)(55,583)(59,097)(60,698)(41,554)(70,959)
Other undisclosed operating income     7,826 
Operating loss:(82,605)(55,583)(59,097)(60,698)(33,728)(70,959)
Nonoperating income (expense)7,4732,923(42)64511,517
Investment income, nonoperating8,4672,951 19490 
Gain (loss), foreign currency transaction, before tax    (1)5 
Other nonoperating income (expense)(994)(28) (12)(44)1,518
Interest and debt expense(12)(12)(8)(12)(14)(1)
Other undisclosed income from continuing operations before equity method investments, income taxes     141
Loss from continuing operations before equity method investments, income taxes:(75,144)(52,672)(59,147)(60,704)(33,277)(69,442)
Other undisclosed income from continuing operations before income taxes 16,3551,56912  
Loss from continuing operations:(75,144)(36,317)(57,578)(60,692)(33,277)(69,442)
Loss before gain (loss) on sale of properties:(60,692)(33,277)(69,442)
Net loss:(75,144)(36,317)(57,578)(60,692)(33,277)(69,442)
Other undisclosed net income attributable to parent   21   
Net loss available to common stockholders, diluted:(75,144)(36,317)(57,557)(60,692)(33,277)(69,442)

Comprehensive Income ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(75,144)(36,317)(57,578)(60,692)(33,277)(69,442)
Comprehensive loss, net of tax, attributable to parent:(75,144)(36,317)(57,578)(60,692)(33,277)(69,442)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: